InvestorsHub Logo
Followers 56
Posts 8437
Boards Moderated 0
Alias Born 05/14/2015

Re: Cave In Temptor post# 13513

Tuesday, 07/28/2015 10:38:23 AM

Tuesday, July 28, 2015 10:38:23 AM

Post# of 32022
Sanofi has been aware of Afrezza for a long time and knew first hand what it could do since the beginning of initial clinical trials. I believe Sanofi was always the behind the scenes partner for Mannkind while Afrezza made its tortured path to approval. Sanofi also realizes that Afrezza could cannibalize the vast majority if diabetes drugs out there, including Basal if Afrezza's action takes stress of the pancreas and brings it back to a more normal state allowing T1s to not need as much basal. Many think this will hurt Sanofi and in some ways it might. But if Afrezza takes off, the only game in town for diabetics T1 or T2 will be what is supplied by Sanofi and only Sanofi. They have the chance to corner the diabetes med market.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MNKD News